Fort Worth, TX – According to filings with the U.S. Securities and Exchange Commission, Nacuity Pharmaceuticals is raising $11,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Halden Conner played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nacuity Pharmaceuticals

Nacuity Pharmaceuticals, Inc. is a clinical stage pharmaceutical company whose mission is to develop a breakthrough treatment for retinitis pigmentosa (RP) and potentially other ophthalmological indications. Our lead technology is based on studies from the laboratory of Dr. Peter Campochiaro at the Wilmer Eye Institute involving oxidative stress in the retina. Nacuity has assembled an accomplished team and has received significant financial and technical support from the Foundation Fighting Blindness (FFB). The mission of FFB is to drive research providing prevention, treatments and cures for people affected by blinding retinal diseases. Over the last nearly 50 years, FFB has invested over $700 million in this effort. FFB is a significant supporter of Dr. Campochiaro’s research and of Nacuity’s trials through a matching program grant to, and direct investment in, Nacuity.

To learn more about Nacuity Pharmaceuticals, visit http://www.nacuity.com/

Contact:
Halden Conner, President and Chief Executive Officer
817-336-3000
halden@nacuity.com
https://www.linkedin.com/in/halden-conner-0690a71a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved